constipation
Conditions
Interventions
Oral administration of Daikenchuto 1.5g/day in 2 or 3 divided doses before meals or between meales for 17days.
Sponsors
Izumo-city general medical center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with abdominal bloating 2)Patients with constipation or who are diagnosed with constipation- predominant irritable bowel syndrome (Rome3 criteria) 3)Patients who can stop on-demand use of laxatives (Daily use is available) 4)Patients whose liver function measured in 6 months are less than the institutional upper limit of normal 5)Age: more than or equal to 20 years at the time of providing informed consent 6)Patients who can provide written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients with organic lesion such as inflammatory bowel disease (ulcerative colitis, Crohn disease) and cancer 2)Patients with signs of gastrointestinal obstruction or a history of total gastrectomy or colectomy but not appendicectomy 3)Patients who took Kampo medicines within 2 weeks 4)Patients who took antibiotics within 2 weeks 5)Patients who changed usage or adoministration of lactobacillus preparation, antacid, prokinetics, calcium polycarbophil, anticholinergics, laxatives, antidepressants, antianxiety drugs within 2 weeks 6)Patients with serious complications (liver, kidney, heart, circulatory, or metabolic disorder) 7)Patients who are lactating, pregnant or considering conception 8)Others, including patients who are unfit for the study as determined by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GSRS score | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)brease hydrogen 2)Nunber of bowel movements 3)Stool form and abdominal synptom 4)Abdominal fullness,overall evaluations(VAS) | — |
Countries
Japan
Outcome results
None listed